Merck & Co., Inc.

MRK Healthcare Drug Manufacturers - General NYSE

PDF Back to Search

$99.72

$-1.17 (-1.16%)

Open: $101.40 | High: $102.09 | Low: $99.19 | Prev Close: $100.89

Market Cap: $250.62B

Volume: 10.4M | Avg: 13.1M

Last updated: December 05, 2025 at 10:05 PM
Investment Rating
A-

Buy

Overall Score: 80/100

Rating Breakdown:
DCF Score 5/5
100%
Strong Buy
ROE Score 5/5
100%
Strong Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 3/5
60%
Neutral
P/B Score 2/5
40%
Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 580

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 75
Growth 20
Market Sentiment 20
Risk 40
Lower is better
Valuation 55
Momentum 25
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 13.19
P/B Ratio 4.80
P/S Ratio 3.90
EPS $7.56
Beta 0.30
Shares Outstanding 2.51B
Price Range & Moving Averages
52-Week High $105.84
52-Week Low $73.31
SMA 50 $89.87
SMA 200 $84.76
Dividend Information
Dividend Yield 3.25%
Annual Dividend $3.24
Earnings
Next Earnings February 03, 2026 11:30 AM ET
Financial Ratios
Margins
Gross Margin 78.3%
Operating Margin 36.4%
Net Margin 29.6%
Returns
ROE 38.9%
ROA 17.1%
Liquidity & Leverage
Debt/Equity 0.80
Current Ratio 1.66
Quick Ratio 1.44
Balance Sheet
Total Assets $117.11B
Total Liabilities $70.73B
Total Equity $46.31B
Cash $13.24B
Total Debt $38.27B
Net Debt $25.03B
Income Statement
Revenue $64.17B
Gross Profit $48.98B
Operating Income $20.22B
Net Income $17.12B
EBITDA $25.71B
Revenue/Share $25.71
Cash Flow
Operating CF $21.47B
CapEx $3.37B
Free Cash Flow $18.10B
Book Value/Share $20.76
Tangible Book/Share $5.98
Equity/Share $20.76
Technical Indicators
RSI (14) 66.98 Neutral
MACD
4.10 Signal: 3.87
Volatility 32.00%
Trading Signal Bullish
Performance & Returns
Total Returns
1 Year +16.5%
Risk-Adjusted Returns
Sharpe Ratio 0.59 Fair
Volatility (Ann.) 30.65% Moderate
vs S&P 500 (SPY)
MRK (1Y) +16.5%
S&P 500 (1Y) +11.86%
Alpha (Excess Return) +4.63%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 59 peers in Healthcare
Metric MRK Sector Avg Percentile
P/E Ratio 13.19 31.51 17%
P/B Ratio 4.8 -0.64 65%
ROE (%) 38.95% 9.31% 85%
Net Margin (%) 29.63% 9.71% 92%
Stock Score 580 503.0 85%
1Y Return (%) +16.50% +4.22% 76%
Percentile: 0% = worst in sector, 100% = best in sector
Historical Price Analysis (Last 200 Days)
Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
MRK $99.72 $102.17 $102.69 $99.89 $89.87 $84.76 66.98 4.10 32.00% 12770712 Weak Short Price Below SMAs
Candlestick Patterns

There wasn't any recognizable pattern for the MRK stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
MRK These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them? Neutral fool.com Read More
MRK Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case Positive wsj.com Read More
MRK Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors Neutral benzinga.com Read More
MRK Can Merck's New Products Aid Growth as Keytruda LOE Test Looms? Positive zacks.com Read More
MRK FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis) Neutral businesswire.com Read More
Company Information

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CEO Robert Davis
Employees 73000
Country US
IPO Date 1978-01-13
Exchange NYSE
Website https://www.merck.com
Sector Healthcare
Industry Drug Manufacturers - General
Similar Stocks (Healthcare - Drug Manufacturers - General)
LLY

Eli Lilly and Company

Price: $1010.31
Change: -0.41%
Market Cap: $9075B
P/E: 49.55
Score: D (580)
View Details
JNJ

Johnson & Johnson

Price: $201.93
Change: -0.27%
Market Cap: $4865B
P/E: 19.51
Score: D (555)
View Details
ABBV

AbbVie Inc.

Price: $226.08
Change: -1.15%
Market Cap: $3995B
P/E: 172.58
Score: E (405)
View Details
AMGN

Amgen Inc.

Price: $329.89
Change: -3.02%
Market Cap: $1776B
P/E: 25.51
Score: E (465)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.